# Treatment options for metastatic breast cancer
Treatment of metastatic breast cancer is strongly tailored to the biological properties of the tumor and where it has spread. The goals are usually to slow growth, relieve symptoms, and maintain quality of life for as long as possible. Treatment is almost always long-term and is regularly adjusted based on how well it works.
Hormone-sensitive forms (HR+/HER2−)
**Hormonal therapy with CDK4/6 inhibitors**
ProveniIncluded in official guidelines, or approved by EMA or FDA
This is often the first treatment for hormone-sensitive metastatic breast cancer. Hormonal agents (usually aromatase inhibitors or fulvestrant) block the action of estrogen, which drives many of these tumors. CDK4/6 inhibitors are agents that suppress cellular proteins needed for tumor growth. They are given together.
This combination slows tumor growth and extends periods during which patients remain stable. Common side effects include fatigue, diarrhea, reduced white blood cells (which can increase infections), and nausea. Regular blood tests monitor these effects.
**Hormonal therapy without CDK4/6 inhibitors**
ProveniIncluded in official guidelines, or approved by EMA or FDA
For patients not suitable for CDK4/6 inhibitors, or after exhausting that option, hormone-blocking agents are continued alone or switched. These include aromatase inhibitors or the selective estrogen receptor modulator toremifene. They work by suppressing estrogen production or binding.
Side effects are usually mild: joint pain, hot flashes, dry eyes, and vaginal symptoms can occur. The risk of osteoporosis increases with long-term use.
**Bisphosphonates**
ProveniIncluded in official guidelines, or approved by EMA or FDA
Bisphosphonates are primarily used in patients with bone metastases. They suppress bone breakdown and can prevent skeletal-related complications (fractures, pain). Recent research suggests possible survival benefits, especially for certain tumor types.
Common side effects include jaw pain, inflammation of the jawbone (rare), and sometimes nausea. Regular dental and eye checkups are recommended.
HER2-positive forms
**HER2-targeted therapy with chemotherapy**
ProveniIncluded in official guidelines, or approved by EMA or FDA
Tumors that express high levels of HER2 (human epidermal growth factor receptor 2) can be treated with HER2-blocking agents. These are often monoclonal antibodies (trastuzumab, pertuzumab) or small-molecule inhibitors (lapatinib, tyrosine kinase inhibitors). These are often combined with chemotherapy.
These combinations can yield longer periods of stabilization. Possible side effects include cardiac effects, hair loss, nausea, and fatigue.
**HER2-targeted therapy without chemotherapy**
ResearchediPositive results in clinical studies, not yet standard treatment
For certain patients with HER2-positive disease, researchers are investigating whether dual HER2 blockade (two different mechanisms of action) without chemotherapy is sufficient. Studies show favorable results for certain groups.
Side effects are generally milder than with combination chemotherapy.
**Chemotherapy in HER2-positive disease**
ProveniIncluded in official guidelines, or approved by EMA or FDA
When HER2-targeted agents lose effectiveness or are not suitable, chemotherapy is applied. This intensifies DNA damage in tumor cells. For metastatic HER2-positive forms, metronomic chemotherapy (lower doses, given more frequently) may be considered.
Typical side effects include hair loss, nausea, fatigue, and increased infection risk due to low white blood cells.
Triple-negative forms (HR−/HER2−)
**Chemotherapy**
ProveniIncluded in official guidelines, or approved by EMA or FDA
Triple-negative cancers do not respond to hormone or HER2-targeted therapy. Chemotherapy is usually the first intervention. This can be given as a single agent or as a combination, depending on overall health and preference.
Side effects are the same as with chemotherapy in general: hair loss, nausea, fatigue, diarrhea, and low white blood cells.
**Immunotherapy**
ResearchediPositive results in clinical studies, not yet standard treatment
Certain triple-negative tumors show immunological characteristics that may make immunotherapy (for example checkpoint inhibitors) favorable. This is being intensively researched in combination with chemotherapy. Initial results are encouraging for certain groups.
Side effects of immunotherapy are distinctive: inflammatory reactions in the lungs, intestines and other organs can occur, alongside fatigue and joint complaints.
**Targeted research (genetic testing)**
ProveniIncluded in official guidelines, or approved by EMA or FDA
Patients with triple-negative cancer can be screened for BRCA mutations or other genetic abnormalities. When certain mutations are present, targeted agents (PARP inhibitors for BRCA mutation) can be used.
Side effects of PARP inhibitors include anemia, nausea and fatigue.
Symptom-directed treatment
**Radiotherapy**
ProveniIncluded in official guidelines, or approved by EMA or FDA
When metastatic disease is locally symptomatic (for example bone pain or brain metastases with neurological complaints), radiotherapy is applied. This can be a few brief treatments (hypofractionation) or traditionally more sessions. The aim is symptom relief and infection risk reduction.
Side effects depend on the irradiated area: skin irritation, fatigue, and very rarely permanent damage to underlying organs.
**Supportive agents against bone complications**
ProveniIncluded in official guidelines, or approved by EMA or FDA
With bone metastases, agents such as denosumab (RANKL inhibitor) are sometimes given alongside bisphosphonates. These further inhibit bone resorption. Regular monitoring for hypocalcemia (too little calcium in the blood) is needed.
**Palliatives for pain and fatigue**
ProveniIncluded in official guidelines, or approved by EMA or FDA
Pain relief, sleep support and energy management are core components. Research into graded exercise therapy (gradually progressive physical activity) and cognitive-behavioral support for fatigue show initial positive results.
Experimental approaches
**Tumor-infiltrating lymphocytes (TIL)**
ExperimentaliOngoing in study setting, outcome still unknown
This is an advanced cell therapy in which the body's own immune cells are harvested from the tumor, multiplied in the laboratory and reinjected. This is ongoing in clinics as research for certain forms.
**CAR-T cell therapy**
ExperimentaliOngoing in study setting, outcome still unknown
Similar to TIL: immune cells are genetically modified to better recognize tumor cells. This is in early research phases for breast cancer.
**Personalized immunotherapy based on tumor characteristics**
ResearchediPositive results in clinical studies, not yet standard treatment
Laboratory analysis of tumor abnormalities (mutations) sometimes helps to select immunotherapy or targeted agents. Studies are underway on the effectiveness of this approach (for example ComboMATCH trial).
Supportive and palliative care
Managing side effects is at least as important as the tumor itself. This includes nutritional support, psychological guidance, symptom management (pain, nausea) and exercise programs. For patients with lymphedema (swelling due to compromised lymphatic system) physical therapy and compression are standard.
Recent research points to possible benefits of timing of nutrition (for example time-restricted eating) for energy management and resilience, although this concerns small pilot studies.
---
_This information never replaces a doctor's judgment. Always discuss your situation with your own healthcare provider._